- Home
- HIFS vs KALV Comparison
HIFS vs KALV Comparison
Compare HIFS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- KALV
- Stock Information
- Founded
- HIFS 1834
- KALV N/A
- Country
- HIFS United States
- KALV United States
- Employees
- HIFS N/A
- KALV N/A
- Industry
- HIFS Major Banks
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- HIFS Finance
- KALV Health Care
- Exchange
- HIFS Nasdaq
- KALV Nasdaq
- Market Cap
- HIFS 595.7M
- KALV 551.2M
- IPO Year
- HIFS N/A
- KALV N/A
- Fundamental
- Price
- HIFS $293.29
- KALV $13.32
- Analyst Decision
- HIFS
- KALV Strong Buy
- Analyst Count
- HIFS 0
- KALV 8
- Target Price
- HIFS N/A
- KALV $26.43
- AVG Volume (30 Days)
- HIFS 55.5K
- KALV 1.3M
- Earning Date
- HIFS 10-10-2025
- KALV 11-10-2025
- Dividend Yield
- HIFS 0.92%
- KALV N/A
- EPS Growth
- HIFS 94.74
- KALV N/A
- EPS
- HIFS 20.54
- KALV N/A
- Revenue
- HIFS $90,528,000.00
- KALV $1,426,000.00
- Revenue This Year
- HIFS N/A
- KALV N/A
- Revenue Next Year
- HIFS N/A
- KALV $234.65
- P/E Ratio
- HIFS $13.34
- KALV N/A
- Revenue Growth
- HIFS 54.99
- KALV N/A
- 52 Week Low
- HIFS $209.71
- KALV $7.30
- 52 Week High
- HIFS $320.00
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- HIFS 58.05
- KALV 58.50
- Support Level
- HIFS $249.58
- KALV $12.82
- Resistance Level
- HIFS $278.76
- KALV $13.75
- Average True Range (ATR)
- HIFS 13.34
- KALV 0.88
- MACD
- HIFS 0.40
- KALV 0.13
- Stochastic Oscillator
- HIFS 95.50
- KALV 64.25
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.